Voluntary Scheme for Branded Medicines Pricing and Access | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

482,622 results for “Voluntary Scheme for Branded Medicines Pricing and Access”

Trials

View all 432701 →

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

87 participants · First posted Jun 23, 2021

Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules

90 participants · First posted Jan 29, 2014

Approved For Marketing

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

First posted Sep 27, 2010

Drugs

View all 5901 →

antimalarials (Medicines for Malaria Venture)

21A092 (MMV Medicines for Malaria Venture)

E-1511

Organizations

View all 3012 →

MEDICINES DEVELOPMENT FOR GLOBAL HEALTH LIMITED

Australia

NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE

Japan

INSTITUTE FOR BREATHING AND SLEEP

Australia

News

View all 41008 →

UK Unveils New Five-Year Drug Pricing Agreement to Accelerate NHS Medicine Access

UK Life Sciences Council Lacks Transparency Despite Critical Industry Role

Shifting Landscape: 5EU Markets Show Significant Changes in HTA Decisions and Drug Pricing in Q1 2025

Page 1 of 48263